90%(1) - Suplasyn

Easy and safe
Easy and safe
SUPLASYN® IMPROVES joint function with an EASY & SAFE INJECTION
a fast* and long lasting** effect (up to 6 months),
Proven by clinical studies (1,2,3,4,5)
• Fast* improvement of pain
(4)
• Fast* and long lasting** improvement of functionality
easy FOR DOCTORS TO INJECT
(1,4)
Proven
docum and
ented
Patient
and Do
c
high sa
tisfactiotor
n
>90%
safe for the patient
(1)
COMPLETE RANGE SUITABLE FOR ALL TYPES OF JOINTS
Watch
injection
tecniques
video
Comparison of avian and
nonavian hyaluronic acid in
osteoarthritis of the knee
Suplasyn®
20mg/2ml
The Regular choice
Watch
injection
tecniques
video
Suplasyn® 1-Shot
60 mg/6 ml
The comfort choice
Watch
injection
tecniques
video
Suplasyn® m.d.
7 mg/0.7 ml
The specific choice
Petrella R, Cogliano A, Decaria J. Orthopedic
Research and Reviews 2010:2 5–9
1- Gydek A et al. ¨Efficacy and safety of intra-articular use of Hyaluronic acid (Suplasyn®) in the treatment of knee osteoarthritis¨ Przegl Lek. 2011;68(6)
307-10. 2- Blanch J et al. ASKOT STUDY: Effectiveness and safety of a 1-shot injection of sodium Hyaluronate for knee osteoarthritis treatment.
Springer Experience & Drug Evidence. 3- Montfort J et al. Data on file. 4- Petrella R J: Hyaluronic acid for the treatment of knee osteoarthritis:
Long-term outcomes from a naturalistic primary care experience. Am J Phys Med Rehabil 2OO5;84:287- 283 5- Mazières B et al. Medicoeconomic
evaluation of hyaluronic acid for knee osteoarthritis in everyday practice: The MESSAGE study. Joint Bone Spine 74 (2007) 453e460.
SUP 201312-3
*The significant improvement in walking VAS pain was seen at visit 2, 1 week after the first injection (22.7%, p< 0.04)(4) **6 months (4)
www.suplasyn.com
AAFFptsptAvian_2SPSN.indd 1
31/03/14 19:27
OBJECTIVE
• To compare the efficacy and safety of avian and nonavian origin Hyaluronic
acid (HA) in the treatment of knee osteoarthritis (OA) during a long-term
follow-up (around 5 years).
Methods
• Patients with knee OA were allocated to receive avian or non avian HA as
per their preference .
• Both avian and nonavian HA products were delivered at 2 mL once weekly
over three weeks (one series). Series of treatment were separated by at
least 26 weeks (up to 10 series).
• The primary outcome measure was the restingVAS for pain. Also weightbearing pain, patient satisfaction with treatment using a 5-point categorical
scale (1 = no satisfaction, 5 = extremely satisfied), numbers of HA series,
number of medication taken for pain and adverse events were recorded in
each visit. Analyses were conducted using a ITT approach*.
Results
• A total of 4,412 patients evaluated for inclusion: 1,726 received avian versus
1,971 patients nonavian HA injections over 10 consecutive series.
• VAS resting pain after the 10th consecutive series revealed no significant
difference in VAS change compared to baseline (Table).
• Weight-bearing VAS pain reduction was significantly higher in nonavian HA
than in avian HA (p<0,01).
• The number of concomitant pain therapies and adverse events were
significantly greater in the avian vs nonavian group (p<0,01). Adverse
events included pain (>80% of the events), effusion, erythema.
Percent improvement in resting VAS pain with first and 10th HA series
First series
10th series
Avian
Non avian
Avian
Non avian
Resting pain
(reduction form baseline)
-4,8±2.0
-5.1±2.0
-5.2±2.2
-5.5±2.1
Weight-bearing
(reduction from baseline)
-6.1±1.4
-6.1±1.9
-7.2±2.6
-8.8±1.8*
VAS resting and weight-bearing pain scores (improvement from baseline)
Note: *P<0.001.
AAFFptsptAvian_2SPSN.indd 2
31/03/14 19:27
Conclusions
Avian and non avian HA therapies
both improve resting pain of OA
patients. Significant differences in
weight bearing pain and in adverse
events tend to say that non avian
HA therapies should be favored as a
treatment of OA from early stage of
the illness.
*Intention-to-treat (ITT) approach provides unbiased comparisons among the treatment groups. Intention to
treat analyses are done to avoid the effects of crossover and dropout, which may break the random assignment
to the treatment groups in a study.
AAFFptsptAvian_2SPSN.indd 3
31/03/14 19:27